Savara, Inc. (SVRA): Price and Financial Metrics

Savara, Inc. (SVRA): $2.86

-0.04 (-1.38%)

POWR Rating

Component Grades

Momentum

B

Stability

C

Sentiment

Quality

C

Add SVRA to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals

Industry

D

Ranked

#104 of 167

in industry

SVRA Price/Volume Stats

Current price $2.86 52-week high $3.01
Prev. close $2.90 52-week low $1.08
Day low $2.81 Volume 329,000
Day high $2.97 Avg. volume 243,435
50-day MA $2.08 Dividend yield N/A
200-day MA $1.82 Market Cap 326.23M

SVRA Stock Price Chart Interactive Chart >


Savara, Inc. (SVRA) Company Bio


Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is based in Austin, Texas.


SVRA Latest News Stream


Event/Time News Detail
Loading, please wait...

SVRA Latest Social Stream


Loading social stream, please wait...

View Full SVRA Social Stream

Latest SVRA News From Around the Web

Below are the latest news stories about SAVARA INC that investors may wish to consider to help them evaluate SVRA as an investment opportunity.

Savara to Present at the Jefferies Healthcare Conference

AUSTIN, Texas, June 02, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT. A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

Yahoo | June 2, 2023

Independent Director of Savara David Ramsay Buys 4.8% More Shares \

Potential Savara Inc. ( NASDAQ:SVRA ) shareholders may wish to note that the Independent Director, David Ramsay...

Yahoo | May 28, 2023

Why Shares of Savara Jumped on Tuesday

The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.

Yahoo | May 16, 2023

Savara Reports First Quarter Financial Results and Provides Business Update

AUSTIN, Texas, May 15, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2023 and provided a business update.

Yahoo | May 15, 2023

Savara Announces New Employment Inducement Grant

AUSTIN, Texas, May 05, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

Yahoo | May 5, 2023

Read More 'SVRA' Stories Here

SVRA Price Returns

1-mo 40.89%
3-mo 13.49%
6-mo 77.64%
1-year 104.29%
3-year 17.70%
5-year -69.64%
YTD 84.52%
2022 25.00%
2021 7.83%
2020 -74.33%
2019 -40.82%
2018 -48.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!